Akari Therapeutics Plc Stock Today
| AKTX Stock | USD 1.03 0.27 20.77% |
Performance0 of 100
| Odds Of DistressOver 85
|
Akari Therapeutics is trading at 1.03 as of the 26th of November 2024; that is 20.77 percent decrease since the beginning of the trading day. The stock's open price was 1.3. Akari Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Akari Therapeutics PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of January 2024 and ending today, the 26th of November 2024. Click here to learn more.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Akari Therapeutics, Plc is based in London, the United Kingdom. Akari Therapeutics is traded on NASDAQ Exchange in the United States.. The company has 20.65 M outstanding shares of which 21.29 K shares are presently shorted by private and institutional investors with about 1.92 trading days to cover. More on Akari Therapeutics PLC
Moving together with Akari Stock
Moving against Akari Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Akari Stock Highlights
| CEO President | Samir MD |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Akari Therapeutics PLC (AKTX) is traded on NASDAQ Exchange in USA. It is located in 22 Boston Wharf Road, Boston, MA, United States, 02210 and employs 6 people. Akari Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.35 M. Akari Therapeutics PLC conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 20.65 M outstanding shares of which 21.29 K shares are presently shorted by private and institutional investors with about 1.92 trading days to cover.
Akari Therapeutics PLC currently holds about 8.15 M in cash with (16.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14.
Check Akari Therapeutics Probability Of Bankruptcy
Ownership AllocationAkari Therapeutics holds a total of 20.65 Million outstanding shares. Akari Therapeutics PLC shows 11.9 percent of its outstanding shares held by insiders and 0.5 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Akari Ownership Details
Akari Therapeutics PLC Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Akari Therapeutics market risk premium is the additional return an investor will receive from holding Akari Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.19) | |||
| Jensen Alpha | (1.67) | |||
| Total Risk Alpha | (2.83) | |||
| Treynor Ratio | 1.95 |
Akari Stock Against Markets
Akari Therapeutics Corporate Management
| Torsten Hombeck | Chief Officer | Profile | |
| Annie Mack | Financial Controller | Profile | |
| MD III | Executive Officer | Profile | |
| Ray MD | Ex Chairman | Profile | |
| BethAnne Lang | Senior Affairs | Profile |
Already Invested in Akari Therapeutics PLC?
The danger of trading Akari Therapeutics PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Akari Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Akari Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Akari Therapeutics PLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.